12,843 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Purchased by Alpha DNA Investment Management LLC

Alpha DNA Investment Management LLC purchased a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the 3rd quarter, HoldingsChannel reports. The firm purchased 12,843 shares of the company’s stock, valued at approximately $411,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SWTX. Vanguard Group Inc. grew its position in SpringWorks Therapeutics by 8.2% in the first quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company’s stock worth $321,373,000 after acquiring an additional 492,783 shares in the last quarter. American International Group Inc. grew its position in SpringWorks Therapeutics by 1.2% in the first quarter. American International Group Inc. now owns 33,751 shares of the company’s stock worth $1,661,000 after acquiring an additional 394 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its position in SpringWorks Therapeutics by 20.3% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock worth $220,000 after acquiring an additional 754 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in SpringWorks Therapeutics by 48.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock worth $202,318,000 after acquiring an additional 1,333,892 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in shares of SpringWorks Therapeutics by 254.2% during the first quarter. Jane Street Group LLC now owns 580,938 shares of the company’s stock valued at $28,594,000 after buying an additional 416,942 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SWTX. JPMorgan Chase & Co. boosted their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Wedbush restated an “outperform” rating and set a $77.00 target price on shares of SpringWorks Therapeutics in a research report on Monday, November 18th. Evercore ISI began coverage on SpringWorks Therapeutics in a research report on Wednesday, November 20th. They set an “outperform” rating and a $60.00 target price for the company. Finally, HC Wainwright dropped their target price on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $67.00.

SpringWorks Therapeutics Trading Up 7.5 %

Shares of NASDAQ SWTX opened at $39.02 on Monday. The stock has a 50 day moving average price of $32.60 and a 200 day moving average price of $36.74. SpringWorks Therapeutics, Inc. has a 52-week low of $20.19 and a 52-week high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.03. The firm had revenue of $49.10 million during the quarter, compared to analyst estimates of $53.28 million. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. SpringWorks Therapeutics’s quarterly revenue was up 4810.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.27) earnings per share. Research analysts predict that SpringWorks Therapeutics, Inc. will post -3.12 earnings per share for the current fiscal year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.